Gullans Steven R. Ph.D. 4
4 · Gemphire Therapeutics Inc. · Filed Feb 12, 2018
Insider Transaction Report
Form 4
Gullans Steven R. Ph.D.
Director
Transactions
- Purchase
Common Stock
2018-02-08$7.00/sh+71,429$500,003→ 930,252 total(indirect: Held by Excel Venture Fund II, L.P.)
Footnotes (2)
- [F1]The shares were purchased in a confidentially marketed public offering pursuant to an Underwriting Agreement. The offering closed on February 12, 2018.
- [F2]The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.